<DOC>
	<DOCNO>NCT02050594</DOCNO>
	<brief_summary>The primary objective protocol identify describe observed adverse event ( AEs ) treatment Ipilimumab advance melanoma Venezuela study period</brief_summary>
	<brief_title>Ipilimumab 12-month Intensive Pharmacovigilance Protocol</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Age 18 year old date first dose Ipilimumab Subjects receive least 1 dose Ipilimumab treatment unresectable , recurrent metastatic melanoma Venezuela Subjects receive Ipilimumab part clinical trial Subjects receive Ipilimumab indication local approval ( ie , unresectable metastatic melanoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>